Johnson & Johnson (NYSE:JNJ) Stake Lessened by Arkadios Wealth Advisors

Arkadios Wealth Advisors trimmed its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 24.9% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 46,192 shares of the company’s stock after selling 15,275 shares during the period. Arkadios Wealth Advisors’ holdings in Johnson & Johnson were worth $6,680,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently bought and sold shares of the company. Spring Capital Management LLC increased its stake in Johnson & Johnson by 11.7% in the 4th quarter. Spring Capital Management LLC now owns 44,932 shares of the company’s stock valued at $6,498,000 after buying an additional 4,691 shares during the period. Dominguez Wealth Management Solutions Inc. raised its holdings in shares of Johnson & Johnson by 1.1% during the fourth quarter. Dominguez Wealth Management Solutions Inc. now owns 23,707 shares of the company’s stock worth $3,429,000 after acquiring an additional 261 shares in the last quarter. Canoe Financial LP boosted its position in Johnson & Johnson by 3.2% during the fourth quarter. Canoe Financial LP now owns 92,626 shares of the company’s stock valued at $13,396,000 after purchasing an additional 2,900 shares during the last quarter. Retirement Wealth Solutions LLC purchased a new position in Johnson & Johnson in the fourth quarter valued at about $73,000. Finally, Brooklyn Investment Group increased its position in Johnson & Johnson by 33.2% in the 4th quarter. Brooklyn Investment Group now owns 16,457 shares of the company’s stock worth $2,380,000 after purchasing an additional 4,099 shares during the last quarter. 69.55% of the stock is owned by hedge funds and other institutional investors.

Johnson & Johnson Stock Down 0.5 %

JNJ opened at $147.03 on Monday. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $168.85. The business has a 50 day moving average of $148.51 and a 200-day moving average of $156.03. The stock has a market capitalization of $353.99 billion, a price-to-earnings ratio of 21.28, a P/E/G ratio of 2.30 and a beta of 0.51. The company has a current ratio of 1.03, a quick ratio of 0.79 and a debt-to-equity ratio of 0.45.

Johnson & Johnson Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th will be given a $1.24 dividend. The ex-dividend date of this dividend is Tuesday, February 18th. This represents a $4.96 annualized dividend and a yield of 3.37%. Johnson & Johnson’s dividend payout ratio is 71.78%.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on JNJ shares. Bank of America lowered their price target on Johnson & Johnson from $166.00 to $160.00 and set a “neutral” rating for the company in a research note on Friday. Royal Bank of Canada increased their price target on shares of Johnson & Johnson from $178.00 to $181.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 16th. Wolfe Research initiated coverage on shares of Johnson & Johnson in a research note on Friday, November 15th. They issued an “outperform” rating and a $190.00 price objective for the company. Morgan Stanley raised their target price on Johnson & Johnson from $169.00 to $175.00 and gave the company an “equal weight” rating in a report on Wednesday, October 16th. Finally, StockNews.com downgraded Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a research note on Friday. Seven investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat.com, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and a consensus target price of $174.29.

Insider Activity

In other news, Director Mark A. Weinberger purchased 1,000 shares of the business’s stock in a transaction on Thursday, December 12th. The stock was purchased at an average price of $147.22 per share, with a total value of $147,220.00. Following the acquisition, the director now directly owns 1,000 shares in the company, valued at approximately $147,220. The trade was a ∞ increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this link. 0.16% of the stock is owned by company insiders.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.